RxDoctor Payments Data

Imran Virk, MD

Interventional Cardiology · Oklahoma City, OKNPI 1497863815

Payments from drug & device makers

$719in general payments, 2019–2025

Across 19 payments — averaging $37.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endologix LLC$381
  • Abiomed$101
  • Gilead$48
  • Kestra Medical Technology Services, Inc.$40
  • Pfizer$28
  • Merck$28
  • plus $92 from 5 others

What the payments were for

  • Food & beverage$719100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$719 in reported general payments places this provider in the 5th percentile of 110 interventional cardiology providers in Oklahoma.

See all interventional cardiology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$406,816
Medicare patients
1,769
Services billed
5,730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban914$891,481
XareltoRivaroxaban150$190,157
FarxigaDapagliflozin Propanediol203$182,766
EntrestoSacubitril/Valsartan169$169,632
Repatha SureclickEvolocumab134$132,147
BrilintaTicagrelor103$63,704
JardianceEmpagliflozin64$63,052
Repatha SyringeEvolocumab42$40,654
CorlanorIvabradine Hcl33$36,547
Metoprolol Succinate1,733$29,097
Atorvastatin Calcium1,831$23,362
Rosuvastatin Calcium1,204$21,883
Ranolazine ErRanolazine199$17,652
Ezetimibe466$10,817
Omega-3 Acid Ethyl Esters127$10,335

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$28$891,481914 claims
AmgenCorlanor$14$36,54733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 110 interventional cardiology providers in Oklahoma.

Other interventional cardiology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →